CDR3β peptides identified in the specificity group can recognize cells with the TEAD1 neoantigen; therefore, CD8+ cells in patients harboring the receptors can target ovarian cancer-initiating cells for destruction, reducing chemoresistance and the probability of recurrence. Here, TEAD1 is linked to ovarian carcinoma.